NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biotechnology company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the first patient has been enrolled in a hepatitis C trial with NOV-205, the company’s second compound. The initial U.S.-based double-blind, placebo-controlled Phase 1b trial will evaluate NOV-205 versus placebo as monotherapy in 30 chronic hepatitis C genotype 1 patients who previously failed treatment with pegylated interferon plus ribavirin. A link to the trial description and contact information is available at www.novelos.com on the ‘Clinical Trials’ page.
